PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial

被引：4
|
作者：
Prat, A. [1 ]
Brase, J. C. [2 ]
Cheng, Y. [3 ]
Nuciforo, P. [4 ]
Pare, L. [1 ]
Pascual, T. [1 ]
Martinez, D. [1 ]
Galvan, P. [1 ]
Vidal, M. [1 ]
Adamo, B. [1 ]
Hortobagyi, G. [5 ]
Baselga, J. [6 ]
Ciruelos, E. [7 ]
机构：
[1] Hosp Clin Barcelona, Dept Clin Oncol, Barcelona, Spain
[2] Novartis Pharma AG, Precis Med, Basel, Switzerland
[3] Novartis Pharma AG, Biostat, Basel, Switzerland
[4] Vall dHebron Inst Oncol, Mol Oncol, Barcelona, Spain
[5] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
[6] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[7] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
10.1016/S0959-8049(18)30574-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
404 (PB-03
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [31] EFFICACY plus SAFETY OF PALBOCICLIB (P) IN PATIENTS (PTS) ≤50 Y WITH HORMONE RECEPTOR- POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP ANALYSIS OF 2 RANDOMIZED PHASE 3 STUDIES
    Cristofanilli, Massimo
    Harbeck, Nadia
    Rugo, Hope
    Castrellon, Aurelio
    Joy, Anyl A.
    Verma, Sunil
    Im, Seock-Ah
    Iyer, Shrividya
    Puyana, Kathy
    Gauthier, Eric
    Huang, Xin
    Bartlett, Cynthia Huang
    Loibl, Sibylle
    Finn, Richard S.
    [J]. BREAST, 2018, 41 : S11 - S12
  • [32] Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
    Cottu, P. H.
    Ring, A.
    Marchetti, P.
    Cardoso, F.
    Salvador, J.
    Neven, P.
    Papazisis, K.
    Campone, M.
    Bachelot, T.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    De laurentiis, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S379 - S380
  • [33] XENERA™-1: A phase II trial of xentuzumab (Xe) in combinationwith everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement
    Schmid, Peter
    Rugo, Hope S.
    Cortes, Javier
    Huang, Dennis Chin-Lun
    Crossley, Kate
    Massey, Dan
    Burris, Howard A., III
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 158 - 158
  • [34] Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Burris, Howard A., III
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 201 - 213
  • [35] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
    Chainitikun, Sudpreeda
    Long, James P.
    Rodriguez-Bautista, Ruben
    Iwase, Toshiaki
    Tripathy, Debu
    Fujii, Takeo
    Ueno, Naoto T.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 729 - 739
  • [36] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).
    Slamon, Dennis J.
    Fasching, Peter A.
    Patel, Ravindranath
    Verma, Sunil
    Hurvitz, Sara A.
    Chia, Stephen K. L.
    Crown, John
    Martin, Miguel
    Barrios, Carlos H.
    Spera, Gonzalo
    Lopez, Celine
    Hor, Ines
    Pelov, Diana
    Hughes, Gareth
    Nawinne, Moditha
    Hortobagyi, Gabriel N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) + ribociclib (RIB)
    Slamon, D. J.
    Neven, P.
    Chia, S.
    Fasching, P. A.
    De Laurentiis, M.
    Im, S-A.
    Petrakova, K.
    Bianchi, G. V.
    Esteva, F. J.
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    De la Cruz-Merino, L.
    Beck, J. T.
    Pivot, X.
    Sondhi, M.
    Wang, Y.
    Chakravartty, A.
    Rodriguez-Lorenc, K.
    Jerusalem, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [38] Alpelisib plus letrozole in estrogen receptor-Positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial
    Juric, Dejan
    Goncalves, Anthony
    Hamilton, Erika
    Boni, Valentina
    Mayer, Ingrid A.
    Turri, Sabine
    Wang, Yingbo
    Vogl, Florian D.
    Sellami, Dalila
    Campone, Mario
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [39] Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
    Zhao, Hongmeng
    Li, Dan
    Li, Qian
    Zhang, Bin
    Xiao, Chunhua
    Zhao, Ying
    Ge, Jie
    Yu, Yue
    Jia, Yumian
    Guo, Xiaojing
    Cao, Xuchen
    Wang, Xin
    [J]. ONCOLOGIST, 2024, 29 (06): : e763 - e770
  • [40] COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Chandiwana, D.
    Lanoue, B.
    Delea, T. E.
    [J]. VALUE IN HEALTH, 2020, 23 : S39 - S39
12345